Project Description

Evolution of CML treatment and goals of therapy in 2014:

  • 2nd Gen TKIs in front line setting
  • Benefit of switch from imatinib to nilotinib (ENESTcmr)
  • Potential for discontinuation on imatinib (STOP 2G)
  • Planned and ongoing discontinuation trials (ENESTop)

Dr. Gianantonio Rosti

Department of Hematology and Oncology
'L. and A. Seràgnoli' St Orsola University Hospital - Bologna